99 related articles for article (PubMed ID: 26039555)
1. Omacetaxine (Synribo) for CML.
Med Lett Drugs Ther; 2015 May; 57(1469):e80-1. PubMed ID: 26039555
[No Abstract] [Full Text] [Related]
2. Omacetaxine: the FDA decision.
Berman E
Clin Adv Hematol Oncol; 2011 Jan; 9(1):57-8. PubMed ID: 21326148
[No Abstract] [Full Text] [Related]
3. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.
Mahadeo KM; Cole PD
Blood; 2010 May; 115(18):3852. PubMed ID: 20448119
[No Abstract] [Full Text] [Related]
5. Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?
Damlaj M; Assouline S
Leuk Lymphoma; 2015 Jan; 56(1):6-7. PubMed ID: 24898667
[No Abstract] [Full Text] [Related]
6. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
[TBL] [Abstract][Full Text] [Related]
8. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
[TBL] [Abstract][Full Text] [Related]
9. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
11. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü S; Wang J
J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.
Wetzler M; Kantarjian HM; Nicolini FE; Lipton JH; Akard L; Baccarani M; Khoury HJ; Li E; Munteanu M; Cortes J
Blood Cancer J; 2015 Dec; 5(12):e376. PubMed ID: 26657200
[No Abstract] [Full Text] [Related]
14. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
15. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
[TBL] [Abstract][Full Text] [Related]
16. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
17. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.
Gandhi V; Plunkett W; Cortes JE
Clin Cancer Res; 2014 Apr; 20(7):1735-40. PubMed ID: 24501394
[TBL] [Abstract][Full Text] [Related]
18. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukaemia in India.
Malhotra P; Varma S
Lancet; 2007 Sep; 370(9593):1127. PubMed ID: 17905161
[No Abstract] [Full Text] [Related]
20. Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]